基于胶质母细胞瘤遗传特征的个性化治疗策略验证数据集

数据集获取（Figshare）

• 源站标题：Translational Validation of Personalized Treatment Strategy Based on Genetic Characteristics of Glioblastoma
• DOI：10.1371/journal.pone.0103327
• 发布日期：2014-08-01
• 文件数：2 个
• 文件总体积：12.80 MB
• 源站页面：https://plos.figshare.com/articles/dataset/_Translational_Validation_of_Personalized_Treatment_Strategy_Based_on_Genetic_Characteristics_of_Glioblastoma_/1124589

命令行下载

curl -L -o "Figure_S1.tif" "https://ndownloader.figshare.com/files/1618406"
curl -L -o "Figure_S2.tif" "https://ndownloader.figshare.com/files/1618407"

文件清单

• Figure_S1.tif（544.86 KB）
• Figure_S2.tif（12.25 MB）

文件总体积 12.80 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Glioblastoma (GBM) heterogeneity in the genomic and phenotypic properties has potentiated personalized approach against specific therapeutic targets of each GBM patient. The Cancer Genome Atlas (TCGA) Research Network has been established the comprehensive genomic abnormalities of GBM, which sub-classified GBMs into 4 different molecular subtypes. The molecular subtypes could be utilized to develop personalized treatment strategy for each subtype. We applied a classifying method, NTP (Nearest Template Prediction) method to determine molecular subtype of each GBM patient and corresponding orthotopic xenograft animal model. The models were derived from GBM cells dissociated from patient’'s surgical sample. Specific drug candidates for each subtype were selected using an integrated pharmacological network database (PharmDB), which link drugs with subtype specific genes. Treatment effects of the drug candidates were determined by in vitro limiting dilution assay using patient-derived GBM cells primarily cultured from orthotopic xenograft tumors. The consistent identification of molecular subtype by the NTP method was validated using TCGA database. When subtypes were determined by the NTP method, orthotopic xenograft animal models faithfully maintained the molecular subtypes of parental tumors. Subtype specific drugs not only showed significant inhibition effects on the in vitro clonogenicity of patient-derived GBM cells but also synergistically reversed temozolomide resistance of MGMT-unmethylated patient-derived GBM cells. However, inhibitory effects on the clonogenicity were not totally subtype-specific. Personalized treatment approach based on genetic characteristics of each GBM could make better treatment outcomes of GBMs, although more sophisticated classifying techniques and subtype specific drugs need to be further elucidated.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0103327（source: https://plos.figshare.com/articles/dataset/_Translational_Validation_of_Personalized_Treatment_Strategy_Based_on_Genetic_Characteristics_of_Glioblastoma_/1124589）。